All In Biotech

Investigational drug · Phase 2

DNA Vaccine

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Triple Negative Breast Cancer, Malignant Melanoma, Melanoma (Skin).

Phase 2

Last checked: Nov 20, 2026Latest source record: May 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

496

Any phase or sponsor naming "DNA Vaccine"

First trial start

2019

Aug 19, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "DNA Vaccine", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Triple Negative Breast Cancer
  • Malignant Melanoma
  • Melanoma (Skin)
  • Melanoma Stage III
  • Melanoma Stage IV

Approved drugs for the same conditions: Breast cancer · Melanoma · Oncology · Dermatology

Largest trials

Live from ClinicalTrials.gov: studies naming "DNA Vaccine" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 6,416 on PubMed

Also in development for Triple Negative Breast Cancer

  • SerplulimabHLX10, HLX43Phase 325 trials

    Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage

  • LBL-024Phase 311 trials

    Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma

  • JSKN016Phase 34 trials

    Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer

  • OBI-821OBI-833Phase 32 trials

    OBI Pharma, Inc · Triple Negative Breast Cancer, Non-small Cell Lung Cancer

  • FDA018-ADCPhase 31 trial

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Triple Negative Breast Cancer

  • IL-2MDNA11, Interleukin-2 -albuminPhase 24 trials

    Grit Biotechnology · Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma

  • BT5528nuzefatide pevedotinPhase 23 trials

    BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer

  • BLEX 404 LiquidPhase 22 trials

    BioLite, Inc. · Myelodysplastic Syndrome (MDS), Triple Negative Breast Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.